BioSpace News Archive

When children and adolescents go into cardiac arrest outside of a hospital setting, CPR with rescue breathing – rather than CPR using only chest compressions – leads to better outcomes, according to a new study by researchers at Children’s Hospital of Philadelphia.

Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company’s leadership will participate in four upcoming investor conferences in September 2021.

Neovasc, Inc. today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021.

Avantor, Inc. announced that it will host a virtual investor day on September 9, 2021 starting at 9:00 a.m. Eastern Daylight Time .

OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE ® as a treatment for mild-to-moderate COVID-19.

NEUVOGEN, an immunoncology company, is pleased to announce the appointment of Dr. Jack Bui to its Scientific Advisory Board (“SAB”) effective August 30, 2021 .

VBL Therapeutics announced enrollment of new patients in VB-111 studies in the Unites States will resume immediately following authorization by the U.S. Food and Drug Administration Chemistry, Manufacturing and Controls Group to use new batches of ofranergene obadenovec produced in VBL’s commercial-scale GMP Modiin, Israel facility in clinical studies in the United States.

Renalytix Plc announced the appointment of Daniel J. Levangie to the Company’s board of directors.

Smith+Nephew, the global medical technology business, announces its proprietary OXINIUM Technology has established itself as the best performing bearing with the lowest risk of revision in total hip arthroplasty 1-4, alongside similarly strong clinical performance in knees.5 These results are substantiated by four national and regional joint registries1-4 over the last 20 years with more than 2 million procedures4 to draw from.

Visby Medical™ announced that it has received a 510 clearance and was granted a waiver under the Clinical Laboratory Improvement Amendments of 1988 from the US Food and Drug Administration to market its fast, single-use polymerase chain reaction diagnostic test for the multiplexed detection of sexually transmitted infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis, using a self-collected vaginal swab.